News March 4, 2024 - Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG Read More January 22, 2024 - CalciMedica Announces Private Placement of up to Approximately $55 Million Read More August 9, 2023 - CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP) Read More June 27, 2023 - Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer Read More June 21, 2023 - Metavention’s Renal Denervation Pivotal IDE Study now Approved by FDA for the Treatment of Hypertension Read More June 12, 2023 - CalciMedica Announces Relisting on Nasdaq Read More May 31, 2023 - Association Between Mobilization and Composite Postoperative Complications Following Major Elective Surgery Read More March 20, 2023 - CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement Read More January 9, 2023 - Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG Read More July 11, 2022 - Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes Read More